Literature DB >> 8809221

Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice.

D J Edwards1, S M Bernier.   

Abstract

The effect of various citrus juices and solutions of naringin on CYP3A activity in rat liver microsomes was compared by measuring the formation of 6 beta-hydroxytestosterone from testosterone. Control enzyme activity was reduced by more than 70% by grapefruit juice. Freshly-squeezed sour (Seville) orange juice containing 20% as much naringin was comparable to grapefruit juice in its ability to inhibit microsomal activity. An aqueous solution of naringin at the same concentration as in grapefruit juice produced only a small decrease in 6 beta-hydroxytestosterone formation. Dilution of grapefruit juice with a naringin solution reduced the inhibitory activity of the juice even though naringin concentration did not change. Naringenin did not form under the incubation conditions used indicating that it did not contribute to the inhibition produced by grapefruit juice. Finally, organic extracts of grapefruit juice possessed considerable inhibitory activity even though naringin was not extractable. These data suggest that grapefruit juice inhibits CYP3A activity in vitro and that neither naringin nor naringenin are primarily responsible for this effect. A compound present in both grapefruit juice and Seville orange juice and extractable into organic solvents appears to be responsible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809221     DOI: 10.1016/0024-3205(96)00417-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  18 in total

Review 1.  Aldosterone-related genetic effects in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

2.  Influence of low-dose oral contraceptives, alcohol, and grapefruit on.

Authors:  H Van Vlierberghe; F Van Durme; H Verdievel; M Dhont; M de Vos; A Elewaut
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

3.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

4.  Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.

Authors:  Candida J Rebello; Robbie A Beyl; Juan J L Lertora; Frank L Greenway; Eric Ravussin; David M Ribnicky; Alexander Poulev; Brandon J Kennedy; Hector F Castro; Shawn R Campagna; Ann A Coulter; Leanne M Redman
Journal:  Diabetes Obes Metab       Date:  2019-09-30       Impact factor: 6.577

Review 5.  Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.

Authors:  U Fuhr
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

6.  Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.

Authors:  H H Kupferschmidt; K E Fattinger; H R Ha; F Follath; S Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 7.  The epithelial sodium channel in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

Review 8.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 9.  Grapefruit-drug interactions.

Authors:  Kay Seden; Laura Dickinson; Saye Khoo; David Back
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

10.  Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.

Authors:  C C Libersa; S A Brique; K B Motte; J F Caron; L M Guédon-Moreau; L Humbert; A Vincent; P Devos; M A Lhermitte
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.